Johnson & Johnson (JNJ)vsOwlet Inc (OWLT)
JNJ
Johnson & Johnson
$232.77
+1.27%
HEALTHCARE · Cap: $567.28B
OWLT
Owlet Inc
$5.11
+3.23%
HEALTHCARE · Cap: $145.01M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 89907% more annual revenue ($96.36B vs $107.06M). JNJ leads profitability with a 21.8% profit margin vs -43.0%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
OWLT
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.8%
Fair Value
$136.12
Current Price
$232.77
$96.65 premium
Intrinsic value data unavailable for OWLT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -526.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : OWLT
OWLT has a balanced fundamental profile.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : OWLT
The primary concerns for OWLT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while OWLT is a turnaround play — different risk/reward profiles.
OWLT carries more volatility with a beta of 1.86 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 28/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Owlet Inc
HEALTHCARE · MEDICAL DEVICES · USA
Owlet Inc. is a pioneering leader in infant health technology, focused on enhancing the safety and wellness of newborns through its innovative monitoring solutions. Its flagship product, the Owlet Smart Sock, utilizes advanced pulse oximetry to deliver real-time insights into heart rates and oxygen levels, allowing parents to access crucial health data via mobile devices. As demand for pediatric health monitoring continues to rise, Owlet is strategically positioned to expand its product portfolio and strengthen its market presence. The company's commitment to delivering actionable health information and improving pediatric care aligns closely with institutional investors' interests in the rapidly evolving landscape of health technology.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?